Business Context and Reporting Period
Company: Sheffield Pharmaceuticals, Inc. (Note: Request metadata listed "Theriva Biologics," but the filing text identifies the registrant as Sheffield Pharmaceuticals, Inc.)
Reporting Period: Quarter ended March 31, 2003
Status: Development stage enterprise focused on pulmonary drug delivery technologies (Premaire and Tempo systems). The company has generated minimal revenue and sustained significant operating losses since inception.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 | Inception to Mar 31, 2003 |
|---|---|---|---|
| Total Revenues | $75,000 | $0 | $3,225,045 |
| Net Loss | $(880,863) | $(3,133,583) | $(96,763,771) |
| Net Loss Attributable to Common | $(1,491,896) | $(3,686,246) | $(105,568,838) |
| Cash and Cash Equivalents (End of Period) | $162,811 | $1,056,918 | $162,811 |
| Net Cash Used in Operating Activities | $(471,802) | $(1,783,167) | $(86,706,740) |
| Total Liabilities | $17,487,166 | $16,900,642 | N/A |
| Stockholders' Equity (Deficiency) | $(16,243,182) | $(15,385,984) | N/A |
| Long-Term Debt | $8,500,000 | $8,500,000 | N/A |
| Current Maturities of Long-Term Debt | $1,000,000 | $1,000,000 | N/A |
Material Changes vs. Prior Period
- Revenue: Increased from $0 in Q1 2002 to $75,000 in Q1 2003 due to the initiation of a contract research feasibility study.
- Expenses: Total expenses decreased significantly from $3.1 million in Q1 2002 to $649,088 in Q1 2003.
- Research & Development: Dropped from $1.2 million to $250,250, driven by lower costs for the RSD unit dose product, Premaire development, and Tempo industrialization.
- General & Administrative: Dropped from $1.9 million to $398,838, primarily due to reduced consulting, legal, and severance costs compared to the prior year.
- Liquidity: Cash and cash equivalents declined by approximately $164,000 from the beginning of the period ($327,195) to the end ($162,811).
- Debt: Interest expense increased to $320,110 from $149,831 due to higher borrowings and new short-term promissory notes.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management states that unless the company raises significant capital ($1 million to $2.5 million) within the next 30-60 days, it is unlikely to meet obligations or continue as a going concern. The company may file for bankruptcy if financing is not secured.
- Financing Activities: The company is evaluating private offerings, debt financings, and licensing arrangements. Recent debt includes a $500,000 secured note (9% interest) and amended unsecured notes with shareholders.
- Development Status:
- Premaire Respiratory: Device is industrialized; seeking U.S. licensing partner in 2003. Albuterol Phase III trials anticipated in 2003 pending funding.
- Tempo: Pilot studies completed showing improved drug deposition; seeking collaboration partners.
- Systemic Programs: Morphine and Ergotamine programs paused pending partner acquisition.
- Listing Risk: The company does not currently meet American Stock Exchange (AMEX) listing standards due to a net capital deficiency of $16.2 million. Failure to regain compliance could result in delisting and trading in the over-the-counter market.
- Legal Proceedings: Named as a defendant in a breach of contract lawsuit seeking $100,000 related to a Zambon alliance facilitation fee. The company has filed a counterclaim.
Investor Verification Checklist
- Verify the company's ability to secure the required $1 million to $2.5 million in capital within 30-60 days to avoid insolvency.
- Confirm the status of the AMEX delisting proceedings and the company's plan for compliance.
- Review the terms of the new secured debt financing (9% interest, 100% premium upon maturity) and its impact on future cash flow.
- Assess the progress of licensing negotiations for the Premaire respiratory program, which is critical for future revenue.
- Monitor the outcome of the Leston v. Sheffield Pharmaceuticals litigation and potential counterclaim recovery.